{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:29:04Z","timestamp":1790684944507,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.anai.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T01:16:21Z","timestamp":1470359781000},"page":"115-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist"],"prefix":"10.1016","volume":"117","author":[{"given":"David A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.05.013_bib1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.05.013_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma, and Immunology","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.05.013_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jaip.2015.01.009","article-title":"Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients","volume":"3","author":"Bavbek","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2016.05.013_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti\u2013TNF-alpha agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.anai.2016.05.013_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.anai.2016.05.013_bib7","first-page":"315","article-title":"Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy","volume":"3","author":"Chan","year":"2004","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.anai.2016.05.013_bib8","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.anai.2016.05.013_bib9","first-page":"440","article-title":"Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment","volume":"28","author":"Lucaciu","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.anai.2016.05.013_bib10","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3914::AID-IMMU3914>3.0.CO;2-#","article-title":"Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in\u00a0vitro and in\u00a0vivo","volume":"29","author":"Rodriguez-Palmero","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.20051060","article-title":"Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis","volume":"202","author":"Beyersdorf","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.anai.2016.05.013_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri3192","article-title":"The storm has cleared: lessons from the CD28 superagonist TGN1412 trial","volume":"12","author":"Hunig","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib13","first-page":"740","article-title":"Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial","volume":"12","author":"Horvath","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib14","doi-asserted-by":"crossref","first-page":"h1831","DOI":"10.1136\/bmj.h1831","article-title":"Experimental drug that injured UK volunteers resumes in human trials","volume":"350","author":"Dyer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.anai.2016.05.013_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/eji.201343967","article-title":"Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412\/TAB08","volume":"44","author":"Tabares","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib16","unstructured":"LaCasce AS, Castells MC, Burstein H, et\u00a0al. Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy. UpToDate. http:\/\/www.uptodate.com\/contents\/infusion-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy. Updated January 8,\u00a02016."},{"key":"10.1016\/j.anai.2016.05.013_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.05.013_bib18","unstructured":"Rituxan (rituximab) [package insert]. Cambridge, MA: Biogen Idec Inc; South San Francisco, CA: Genentech Inc;\u00a02011."},{"issue":"suppl 14","key":"10.1016\/j.anai.2016.05.013_bib19","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.anai.2016.05.013_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents-updated diagnosis, management, and treatment","volume":"3","author":"Galvao","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2016.05.013_bib21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network Symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","article-title":"Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy","volume":"28","author":"Price","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2016.05.013_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2500\/108854107781285717","article-title":"The unusual suspects: a surprise regarding reactions to omalizumab","volume":"28","author":"Lieberman","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2016.05.013_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.anai.2010.10.008","article-title":"The safety and interpretability of skin tests with omalizumab","volume":"105","author":"Lieberman","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1081-1206(10)63560-0","article-title":"Characterization of an anaphylactoid reaction to omalizumab","volume":"96","author":"Dreyfus","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/157488611798918692","article-title":"Successful desensitization of three patients with hypersensitivity reactions to omalizumab","volume":"6","author":"Owens","year":"2011","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.anai.2016.05.013_bib30","article-title":"Failure of omalizumab desensitization resulting in anaphylaxis in a patient with severe asthma","volume":"103","author":"Paranjpe","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2007.06.038","article-title":"Severe serum sickness-like syndrome after omalizumab therapy for asthma","volume":"120","author":"Pilette","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anai.2016.05.013_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.anai.2016.05.013_bib34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.anai.2016.05.013_bib35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.anai.2016.05.013_bib36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.05.013_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616302630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616302630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:15:13Z","timestamp":1761052513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616302630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1081120616302630"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.05.013","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}